Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

964 - Safety analysis of chemotherapy for colitis-associated colorectal cancer in Japan


19 Dec 2015


Poster presentation 1


Kenta Nio


Annals of Oncology (2015) 26 (suppl_9): 42-70. 10.1093/annonc/mdv523


K. Nio1, D. Higashi2, H. Kumagai3, S. Arita3, T. Shirakawa4, K. Nakashima5, Y. Shibata6, M. Esaki7, T. Ueki8, M. Nakano3, H. Ariyama3, H. Kusaba3, M. Hirahashi9, Y. Oda9, T. Esaki10, K. Mitsugi11, K. Futami2, K. Akashi1, E. Baba12

Author affiliations

  • 1 Medicine And Biosystemic Science, Kyushu University Hospital, 812-8582 - Fukuoka/JP
  • 2 Surgery, Fukuoka University Chikushi Hospital, Chikushino/JP
  • 3 Medicine And Biosystemic Science, Kyushu University Hospital, Fukuoka/JP
  • 4 Oncology, Miyazaki Prefectural Miyazaki Hospital, 880-8510 - Miyazaki/JP
  • 5 Internal Medicine, University of Miyazaki Hospital, Miyazaki/JP
  • 6 Medical Oncology, Wajiro Hospital, Fukuoka/JP
  • 7 Medicine And Clinical Science, Kyushu University Hospital, Fukuoka/JP
  • 8 Surgery And Oncology, Kyushu University Hospital, Fukuoka/JP
  • 9 Anatomical Pathology, Kyushu University Hospital, Fukuoka/JP
  • 10 Gastrointestinal And Medical Oncology, National Kyushu Cancer Center, 811-1395 - Fukuoka/JP
  • 11 Oncology, Hamanomachi Hospital, Fukuoka/JP
  • 12 Comprehensive Clinical Oncology, Kyushu University Hospital, 812-8582 - Fukuoka/JP


Abstract 964


Inflammatory bowel diseases (IBD) often cause colorectal cancer. Efficacy and safety profile of chemotherapy (CT) for colitis-associated colorectal cancer (CAC) has not been well examined.


Patients with a CAC who were treated with CT between 2000 and 2014 were retrospectively examined.


Twenty-nine patients (median age, 48 years; 23 males) were assessed. Palliative and adjuvant CT were performed in 13 and 16 patients, respectively. Eighteen patients had ulcerative colitis (UC), and 11 had Crohn's disease (CD). Three UC and 7 CD patients were in the active disease phase. Sixteen UC patients (89%) underwent proctocolectomy. Primary tumors were located in the rectum/anus (n = 16), the left colon (n = 9), or the right colon (n = 4). First-line palliative CT regimens were as follows: FOLFOX (fluorouracil (5-FU), leucovorin (LV), and oxaliplatin) (n = 6), FOLFOX + bevacizumab (BV) (n = 3), FOLFOX + cetuximab, FOLFIRI (5-FU, LV, and irinotecan) + BV and others (n = 2). Adjuvant CT regimens were S-1 (n = 7), UFT/LV (n = 3), FOLFOX (n = 2), XELOX (capecitabine and oxaliplatin) (n = 2) and others (n = 2). In palliative CT, the objective response rate was 15%, and median progression free survival and overall survival were 182 and 315 days, respectively. In adjuvant CT, 5-year relapse-free survival rate was 78%. Grade 3/4 adverse events (AE) were observed in 16 patients (55%). While 43% of active CD patients suffered G3/4 AE, no inactive CD patients had G3/4 AE. Dose-reduction was required in 11 patients (38%), 8 of which were due to hematological AE. CT was terminated because of AE in 7 cases, whereas only in 1 case caused by IBD.


While equivalent efficacy to the common colorectal cancer was achieved in adjuvant setting, modest efficacy in palliative setting was shown. CT was safely performed in CAC, however, consideration of the disease activity especially in CD is required.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings